SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. (BNAI) is trending after the closing of its AI licensing partnership in Africa, establishing Skye Africa Intelligence. The community is actively discussing the strong potential for a short squeeze, citing the stock's low float, high cost-to-borrow, and increasing short interest.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending after its HLP004 Phase 2 results for Generalized Anxiety Disorder led to a significant stock sell-off, prompting community discussion over the data's efficacy nuances and ironic jokes about the company's ticker symbol, "$HELP." Investors are debating if the drop is an overreaction typical of biotech or justified by data concerns, with many viewing it as a buying opportunity.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is trending due to a mixed reception to its latest earnings, which included an annual dividend and share buyback announcement, alongside reports of a swing to loss driven by investments in competitive sectors like food delivery. The community is actively debating whether the stock's deep value and strong cash position will overcome persistent underperformance, exacerbated by broader concerns about China's economic outlook and intense market competition.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending after reporting strong quarterly results and significantly raising its future revenue guidance, propelled by robust AI and data center demand. This has sparked widespread optimism among bulls, who anticipate further upside and analyst upgrades, although some in the community express caution regarding the sustainability of the rally.

Nutex Health, Inc. engages in the management and operation of healthcare facilities. It operates through the following segments: Hospital Division, Population Health Management Division, and Real State Division. The Hospital Division is involved in developing and operating a network of micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). The Population Health Division establishes and operates provider networks such as independent physician associations (IPAs). The Real State Division owns land and hospital buildings which are leased to hospital entities. The company was founded in 2011 and is headquartered in Houston, TX.

Nutex Health Inc

Nutex Health is trending following its Q4 earnings, which presented a revenue miss that management clarified with adjustments showing substantial annual growth and robust cash flow, alongside a new $25M share repurchase program. The community is actively debating these financial nuances and largely dismissing a new short report from Capybara Research as an unsubstantiated effort by short sellers to manipulate sentiment.

Pattern Group, Inc. accelerates brands on global ecommerce marketplaces by leveraging proprietary technology and AI. It acquires inventory from brand partners to sell to consumers through online marketplaces, utilizing vast data sets, sophisticated machine learning, and AI models. The company optimizes and automates all levers of ecommerce growth for global brands, enabling full control over advertising, content management, logistics and fulfillment, pricing, forecasting, and customer service. Pattern Group was founded by David Wright and Melanie Alder in 2013 and is headquartered in Lehi, UT.

Pattern Group Inc. - Ordinary Shares - Series A

Pattern Group

Pattern Group (PTRN) is trending after reporting impressive earnings that surpassed expectations, strong forward guidance, and a new share repurchase program. The community is highly optimistic about PTRN's strategic shift to an AI-driven "Agentic Commerce" platform and its potential to capture significant market share from Amazon's evolving fulfillment services, leading many to view it as a compelling long-term growth opportunity.

Gap, Inc. operates as a global apparel retail company, which offers clothing, apparel, accessories, and personal care products for men, women, and children. The firm operates through the following segments: Gap Global, Old Navy Global, Banana Republic Global, Athleta, and Other. The Gap Global segment includes apparel and accessories for men and women under the Gap brand, along with the GapKids, BabyGap, GapMaternity, GapBody, and GapFit collections. The Old Navy Global segment offers clothing and accessories for adults and children. The Banana Republic Global segment provides clothing, eyewear, jewelry, shoes, handbags, and fragrances. The Athleta segment offers fitness apparel for women. The company founded by Donald G. Fisher and Doris F. Fisher in July 1969 and is headquartered in San Francisco, CA.

Gap, Inc.

Gap is a major talking point after its latest earnings report, which highlighted consistent positive comparable sales and a new significant share repurchase program, even as some investors scrutinize the impacts of tariffs and Athleta's performance. The community is actively debating if the company's ongoing turnaround, including new ventures into beauty and accessories, can overcome market headwinds.

Owlet, Inc. is a digital parenting platform, which engages in the provision of real-time data and insights, and parenting solutions. It focuses on developing and marketing its products and content for children. It offers the Owlet BabySat, Owlet OTC Smart Sock, and Owlet Band products that allow the sharing of infant sleep and health data and also provides an end-to-end digital healthcare solution for its customers. It operates through the following geographical segments: Unites States, United Kingdom, and Other. The company was founded by Kurt Workman, Zack Bomsta, Jordan Monroe, and Jacob Colvin in 2012 and is headquartered in Lehi, UT.

Owlet Inc - Ordinary Shares - Class A

Owlet (OWLT) is trending following its latest financial update, which saw a significant market downturn after a near-term revenue outlook fell well below expectations, prompting community discussion despite solid recent performance and continued growth in its FDA-cleared infant monitoring and subscription services.

Methode Electronics, Inc. engages in the manufacture of component and subsystem devices. It operates through the following segments: Automotive, Interface, Industrial, and Medical. The Automotive segment supplies electronic and electromechanical devices, and related products to automobile original equipment manufacturers. The Interface segment provides a variety of copper and fiber-optic interface and interface solutions for the aerospace, appliance, commercial food service, construction, consumer, material handling, medical, military, mining, point-of-sale, and telecommunications markets. The Industrial segment manufactures external lighting solutions, industrial safety radio remote controls, braided flexible cables, current-carrying laminated busbars, and devices. The Medical segment refers to the medical device business. The company was founded by William Joseph McGinley in 1946 and is headquartered in Chicago, IL.

Methode Electronics, Inc.

Methode Electronics is trending following its strategic sale of the dataMate business to Bel Fuse, a move aimed at portfolio refinement and debt reduction to focus on high-density power solutions. The community is weighing mixed recent earnings, which showed a revenue beat but an adjusted EPS miss, alongside updated long-term guidance that narrows revenue expectations but lowers the adjusted EBITDA outlook.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending amidst community frustration over its unconfirmed earnings date, which, coupled with recent high-profile departures from its Qwen AI team, is fueling market uncertainty. Despite a cautious economic outlook for China, many investors view the stock as deeply undervalued, with its extremely oversold technicals and strong AI and Cloud growth potential driving conversation around a potential rebound.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Eli Lilly issued a revenue guidance between $80 billion and $83 billion for fiscal 2026</li><li>For the full year 2025, Eli Lilly’s revenue grew 45% to $65.18 billion.</li><li>CFO Lucas Montarce said the company expects to launch the multidose Zepbound within the next 30 days, according to a Bloomberg report.</li></ul>Shares of Eli Lilly (LLY) jumped 8% in pre-market trading on Wednesday, after the company reported better-than-expected fourth-quarter results and issued a revenue guidance between $80 billion and $83 billion for fiscal 2026, significantly above fiscal 2025 revenue.<a href="https://stocktwits.com/symbol/LLY">LLY shares</a> were up 9.2% after the opening bell.Fourth-quarter revenue surged 43% to $19.3 billion, driven by volume growth from Mounjaro and Zepbound – signalling sustained momentum in its obesity and diabetes portfolio. Analysts had expected a revenue of $17.86 billion, according to Fiscal.ai data. Meanwhile, Q4 earnings increased by 51% to $7.39 per share on a reported basis, compared to Street estimates of $7.22 per share.For the full year, Eli Lilly’s revenue grew 45% to $65.18 billion. LLY expects earnings of $33.50 to $35 per share for full-year 2026.<h2 class="st-heading-2">Mounjaro And Zepbound Drive Revenue Growth</h2>Global revenue for Mounjaro surged 110% to $7.4 billion in Q4 2025, with U.S. sales rising 57% to $4.1 billion on strong demand despite lower realized prices. International revenue jumped to $3.3 billion from $899 million a year earlier, driven mainly by volume growth.U.S. Zepbound revenue climbed 122% to $4.2 billion, fueled by higher demand but partially offset by pricing pressure. Meanwhile, revenue from Verzenio, Eli Lilly’s drug to treat metastatic breast cancer, edged up 3% to $1.6 billion.<h2 class="st-heading-2">Eli Lilly’s Product Pipeline</h2>After the FDA authorized Lilly to market Zepbound in a multidose device last month, CFO Lucas Montarce said the company expects to launch the multidose pen within the next 30 days, according to a report by Bloomberg on Wednesday.In an interview with CNBC last month, CEO Dave Ricks said the upcoming Medicare coverage for obesity drugs could significantly boost the launch of its experimental weight-loss pill, Orforglipron. Ricks added that the company expects Medicare coverage to begin immediately after the drug’s launch.<h2 class="st-heading-2">LLY Pulls Ahead As NOVO Faces Headwinds</h2>Eli Lilly’s optimistic outlook stands in stark contrast to Novo Nordisk (NVO), which expects adjusted sales to decline between 5% and 13% and operating profit to drop by up to 13%. The company cited pricing pressure, intensifying competition, and upcoming patent expiries for the key ingredients in Wegovy and Ozempic in select markets outside the U.S.“This is just more evidence they are dominating the category,” Mizuho’s Jared Holz told Bloomberg of Eli Lilly’s obesity market position. “Novo is playing from behind and everyone knows it.”<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘bearish’ over the past 24 hours, amid ‘high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/LLY_jpg_1dcca688cf.webp" alt="LLY.jpg" width="933" height="102"><figcaption>LLY's Sentiment Meter and Message Volumes on Feb. 4, 2026 | Source: Stocktwits</figcaption></figure>One user said that Lilly proved that with “a good product comes great demand.”<stembedurl>https://stocktwits.com/Bagholding_VKTX/message/643931351</stembedurl>LLY shares have gained around 25% over the past year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-fda-higher-dose-wegovy-nvo-stock-outlook/cZbjThlR4ZM">Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Eli Lilly and Company logo seen displayed on a smartphone. (Photo Illustration by Igor Golovniov/SOPA Images/LightRocket via Getty Images)

LLY Stock Surges On Q4  Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook

LLY Stock - Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

Equity

Fourth-quarter revenue surged 43% to $19.3 billion, above Street estimates of $17.86 billion, according to Fiscal.ai data.

<ul class="summary-bullets"><li>The decision follows a comprehensive review that found no link between GLP-1 RA use and suicidal ideation or behavior.</li><li>The agency conducted a large meta-analysis of 91 placebo-controlled clinical trials involving 107,910 patients.</li><li>The FDA also reviewed data from more than 2.2 million patients using healthcare claims and found no higher risk of self-harm among GLP-1 users versus patients taking other diabetes drugs.</li></ul>The U.S. Food and Drug Administration (FDA) on Tuesday asked drugmakers to remove warnings about suicidal thoughts and behavior from the labels of certain popular weight-loss medications after finding no evidence of increased risk.The request applies to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) approved for obesity, including Novo Nordisk’s (NVO) Wegovy and Saxenda, and Eli Lilly’s (LLY) Zepbound.The decision follows a comprehensive review that found no link between GLP-1 RA use and suicidal ideation or behavior.These warnings were originally included as a precaution, based largely on reports tied to older weight-loss drugs rather than GLP-1 therapies specifically. Notably, GLP-1 medications approved for type 2 diabetes have never carried such warnings, and the FDA said the change will ensure consistent labeling across the drug class.<h2 class="st-heading-2">FDA’s Analysis</h2>The agency conducted a large meta-analysis of 91 placebo-controlled clinical trials involving 107,910 patients. The analysis found no increased risk of suicidal thoughts, self-injurious behavior (SI/B), or other psychiatric adverse events such as depression or anxiety.The FDA also reviewed data from more than 2.2 million patients using healthcare claims and found no higher risk of intentional self-harm among GLP-1 users compared with patients taking other diabetes drugs.The findings reaffirm results from a preliminary FDA review released in early 2024 and align with conclusions from a separate UK review in the same year. The Medicines and Healthcare products Regulatory Agency (MHRA) had found no evidence linking weight-loss and diabetes drugs to suicides or suicidal thoughts.At the time of writing, <a href="https://stocktwits.com/symbol/LLY">LLY</a> and <a href="https://stocktwits.com/symbol/NVO">NVO</a> stocks were trading 0.1% and 0.2% lower, respectively. Retail sentiment for both stocks was in the ‘bullish’ territory.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-bctx-stock-surge-50-today/cmUX95vR4Ic">Why Did BCTX Stock Surge 90% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the United States Food and Drug Administration (FDA) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Clears Popular Weight-Loss Drugs Of Suicide Risk After Review Of Over 100K Patients, Asks Drugmakers To Remove Warnings

The request applies to GLP-1 RAs approved for obesity, including Novo Nordisk’s Wegovy and Saxenda and Eli Lilly’s Zepbound.

LLYX
Defiance Daily Target 2X Long LLY ETF

Feed

News

Sentiment

Fundamentals

Info

Latest LLYX News

LLYXDefiance Daily Target 2X Long LLY ETF